Vernal Keratoconjunctivitis Market

Market Overview:

The 7 major vernal keratoconjunctivitis markets reached a value of US$ 256.6 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 348.5 Million by 2034, exhibiting a growth rate (CAGR) of 2.82% during 2024-2034.

The vernal keratoconjunctivitis market has been comprehensively analyzed in IMARC's new report titled "Vernal Keratoconjunctivitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Vernal keratoconjunctivitis (VKC) refers to a rare, chronic allergic disorder primarily affecting the eyes. It typically emerges in children and young adults, particularly in regions with warmer climates. The condition is characterized by inflammation of both the conjunctiva and the cornea. Symptoms of VKC can be distressing, encompassing intense itching, redness, watery discharge, and sensitivity to light. Individuals suffering from the illness might also experience a foreign body sensation in the eye and discomfort. In severe cases, VKC can lead to visual impairment due to complications, such as corneal ulcers or scarring. The diagnosis of this disorder involves a comprehensive eye examination by an ophthalmologist. Clinical features, patient history, and allergic triggers are considered, along with specialized tests like conjunctival scraping and allergen-specific testing. The presence of typical signs such as large papillae (raised bumps) on the conjunctiva under the upper eyelid is often diagnostic.

The increasing cases of exposure to allergens, including pollen, dust mites, animal dander, etc., that can lead to an exaggerated immune response are primarily driving the vernal keratoconjunctivitis market. In addition to this, the inflating utilization of effective pharmaceutical interventions, such as antihistamines, mast cell stabilizers, and corticosteroids to manage symptoms and avert exacerbations is also creating a positive outlook for the market. Moreover, the widespread adoption of cold compresses and lubricating eye drops, as they aid in alleviating discomfort and maintaining ocular moisture in individuals suffering from the illness, is further bolstering the market growth. Apart from this, the rising usage of immunomodulatory agents, which help to regulate the exaggerated immune response underlying the condition, thereby improving the quality of life, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of advanced therapies like subconjunctival steroid injections to treat severe cases of VKC is also augmenting the market growth. These procedures provide direct delivery of the medication to the affected area and target the inflammation at its source. Furthermore, the escalating application of tele-ophthalmology consultations for remote diagnosis and treatment plans, since they act as a facilitative element in reaching out to a broader patient population, making healthcare more accessible, is expected to drive the vernal keratoconjunctivitis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the vernal keratoconjunctivitis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for vernal keratoconjunctivitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the vernal keratoconjunctivitis market in any manner.

Key Highlights:

• Vernal keratoconjunctivitis is more common in tropical and subtropical regions, as well as in warm and dry environments.
• The prevalence recorded from cooler nations, such as the United States, is 0.29/10000 people.
• In Europe, the prevalence ranged between 1.2 and 12.6 cases per 10,000 people.
• The condition is far more common in areas like Africa, where the stated prevalence ranges from 2 to 37%.
• Vernal keratoconjunctivitis is more prevalent in men. According to a study conducted in Ethiopia, males were 4.23 times more likely than females to have vernal keratoconjunctivitis.

Drugs:

Verkazia is a prescription-only oil-in-water cationic emulsion that enhances cyclosporine absorption and effectively manages vernal keratoconjunctivitis. This treatment inhibits T-cell activation, lowering immune cells and mediators that cause chronic and possibly severe allergic inflammation of the ocular surface in people with vernal keratoconjunctivitis.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the vernal keratoconjunctivitis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the vernal keratoconjunctivitis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current vernal keratoconjunctivitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the vernal keratoconjunctivitis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the vernal keratoconjunctivitis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the vernal keratoconjunctivitis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of vernal keratoconjunctivitis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of vernal keratoconjunctivitis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of vernal keratoconjunctivitis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with vernal keratoconjunctivitis across the seven major markets?
• What is the size of the vernal keratoconjunctivitis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of vernal keratoconjunctivitis?
• What will be the growth rate of patients across the seven major markets?
   

Vernal Keratoconjunctivitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for vernal keratoconjunctivitis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the vernal keratoconjunctivitis market?
• What are the key regulatory events related to the vernal keratoconjunctivitis market?
• What is the structure of clinical trial landscape by status related to the vernal keratoconjunctivitis market?
• What is the structure of clinical trial landscape by phase related to the vernal keratoconjunctivitis market?
• What is the structure of clinical trial landscape by route of administration related to the vernal keratoconjunctivitis market?